Business / Finance RSS Feed - Business / Finance

The Weizmann Institute of Science purchases novel Aeon™ 1GHz NMR system from Bruker

The Weizmann Institute of Science purchases novel Aeon™ 1GHz NMR system from Bruker

The Weizmann Institute of Science in Rehovot, Israel today announced major scientific instrument purchases from Bruker (NASDAQ: BRKR), including a novel Aeon™ 1GHz nuclear magnetic resonance (NMR) system for expanding frontiers in structural biology and intrinsically disordered protein (IDPs) research. Furthermore, the Weizmann Institute is adding an Aeon 600 MHz NMR, a 263 GHz dynamic nuclear polarization (DNP)-NMR system, and a Biospec® 15 Tesla system for preclinical ultra-high field magnetic resonance imaging (MRI). Various NMR and electron paramagnetic resonance (EPR) instrument upgrades round out this major acquisition, instantly propelling the Weizmann Institute to the frontiers of modern magnetic resonance research infrastructure. [More]
SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

SCIEX, a global leader in life science analytical technologies, and QPS Holdings, LLC (QPS), a leading global full-service Contract Research Organization (CRO), today announced a collaboration to advance Hybrid LBA –LCMS, a workflow for routine biologics quantification. Under the agreement, QPS Holdings will deploy the SCIEX BioBA Solution, the first end-to-end and most complete solution for bioanalysis of biologics. [More]
Ontario to invest $4.22 million to support R&D expansion project at Baylis' Mississauga manufacturing plant

Ontario to invest $4.22 million to support R&D expansion project at Baylis' Mississauga manufacturing plant

Ontario is partnering with Baylis Medical Company, a leading supplier of cardiology and radiology products, to support an R&D expansion project at the company’s Mississauga manufacturing plant. [More]

BioTools forms collaborative alliance with Chiral Technologies

BioTools Inc. announced today that it has entered into a cooperative agreement with Chiral Technologies Inc., West Chester, PA, the leader in enantioselective chromatography. [More]

BioTools continues growth, expands products and services in Europe

BioTools, Inc. proudly announces the establishment of its first international subsidary, BioTools Europe, Ltd. [More]
BioAgilytix announces acquisition of IPM Biotech

BioAgilytix announces acquisition of IPM Biotech

BioAgilytix, a leading provider of contract bioanalytical testing services specializing in large molecule bioanalysis, has announced the acquisition of IPM Biotech, a German-based bioanalytical contract research laboratory renowned for its expertise in large molecule bioanalysis, particularly in the area of immunogenicity. [More]

Leica Microsystems deploys Druva inSync to protect, manage access to business data across globe

Druva, the leader in converged data protection, today announced that Leica Microsystems, a multi-national company that develops and manufactures microscopes and other scientific instruments, has deployed inSync for central protection and visibility of data stored on end-user devices. [More]

New Postnova Analytics office opens in UK

Postnova Analytics, the leading international supplier of Field-Flow Fractionation (FFF) systems, has opened a dedicated office to enhance local support for its growing base of UK customers. [More]
ACI announces investment in Sphera Bluoshen to support development of healthcare technology

ACI announces investment in Sphera Bluoshen to support development of healthcare technology

Angola Capital Investments, a leading international investment firm headquartered in Angola, announced its investment in Sphera Bluoshen S.A. to support the development of the finest healthcare technology around the globe. [More]
Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. [More]

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX in the U.S. and Xiapex in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update. [More]
Eclipse Aesthetics partners with Skincential Sciences to distribute Clearista product line

Eclipse Aesthetics partners with Skincential Sciences to distribute Clearista product line

Eclipse Aesthetics, LLC has formed a partnership with Skincential Sciences, a medical diagnostics company in southern California. Eclipse will serve as the exclusive distributor for ClearistaPRO, specially formulated products to safely and effectively remove biomarkers from tissue. [More]
BioLineRx announces year end 2015 financial results, provides operational update

BioLineRx announces year end 2015 financial results, provides operational update

BioLineRx Ltd., a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported its financial results for the year ended December 31, 2015. [More]

Universal Biosensors agrees to modify collaboration arrangements with Siemens Healthcare Diagnostics

Universal Biosensors announced today that it has agreed amendments to its arrangements with Siemens Healthcare Diagnostics Inc. The parties have agreed to shift the focus of their joint product development activities, provide prepayment of milestones to UBI and improved strip pricing to support Siemens’ entry into the point-of-care PT-INR testing market. [More]
Merck reports record results for 2015

Merck reports record results for 2015

Merck, a leading science and technology company, reported record results for 2015, emerging stronger from the transformation process that started in 2007. Net sales and EBITDA pre exceptionals were higher than ever before in Merck’s history of nearly 350 years. [More]
Quantum Plastics acquires wheelchair stabilizing device company, Transfer Solutions

Quantum Plastics acquires wheelchair stabilizing device company, Transfer Solutions

Quantum Plastics, LLC (Quantum) is expanding its product line with the acquisition of the popular wheelchair stabilizing device company, Transfer Solutions. [More]
Ethicon agrees to acquire NeuWave Medical

Ethicon agrees to acquire NeuWave Medical

Ethicon, a medical device company of the Johnson & Johnson family of companies, today announced a definitive agreement to acquire NeuWave Medical, Inc., a privately held medical device company that manufactures and markets minimally invasive soft tissue microwave ablation systems. [More]
New co-marketing deal to make AMRA Profiler protocol available on future GE Healthcare MRI scanners

New co-marketing deal to make AMRA Profiler protocol available on future GE Healthcare MRI scanners

AMRA has announced at the European Congress of Radiology in Vienna, Austria, that it has entered into a new co-marketing agreement with GE Healthcare, a leading provider of MRI systems. [More]
IRIDEX reports revenues of $12.1 million for fourth quarter 2015

IRIDEX reports revenues of $12.1 million for fourth quarter 2015

IRIDEX Corporation today reported financial results for the fourth quarter and year ended January 2, 2016. [More]
CAMH, Impel NeuroPharma partner to advance novel treatment to alleviate depression

CAMH, Impel NeuroPharma partner to advance novel treatment to alleviate depression

The Centre for Addiction and Mental Health and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression. [More]
Advertisement
Advertisement